Bristol Myers Squibb’s Reblozyl reinforces market share in first-line MDS Space
On August 28, the FDA approved the label expansion of Bristol Myers Squibb’s Reblozyl, which is set to improve MDS patients’ quality of life.
On August 28, the FDA approved the label expansion of Bristol Myers Squibb’s Reblozyl, which is set to improve MDS patients’ quality of life.
What's Your Reaction?
